Market By Drug Class, Distribution Channel, End-user, And Geography | Forecast 2019-2028
The Asia-Pacific immunosuppressant drugs market is expected to make progress, with a CAGR of 5.32% in terms of revenue, throughout the estimated years of 2019-2028.
Report scope can be customized per your requirements. Request For Customization
The countries studied in this market include:
•          India
•          Japan
•          China
•          South Korea
•          Australia & New Zealand
•          ASEAN countries
•          Rest of APAC countries
Organ transplantation procedures have been taking place in China since the 1960s, and it has one of the highest rates of organ transplantations globally. In 2004, a record of 13,000 kidney and liver transplants were performed in the country. Moreover, innovative surgical procedures, such as face transplantation, are also performed in the country. All these procedures require the use of immunosuppressant drugs, which help suppress the body’s immune function during the process. This has created a huge demand for immunosuppressants, which, in turn, is fostering the growth of the immunosuppressant drugs market in China.
In India, more than a hundred types of autoimmune diseases have been observed to affect people. In fact, autoimmune disease is one of the top ten causes of death in women and children. By 2020, the country is expected to have more than 14 million disease cases. The steadily growing cases call for the use of immunosuppressant drugs, which is aiding the development of India’s immunosuppressant drugs market over the forecast period.
In addition, as the number of patients awaiting renal transplantation keeps growing in the country, organ supply remains largely inadequate. Around 220,000 people with end-stage kidney disease are in anticipation of a kidney transplant. However, at present, only 250 kidney transplant centers are present in India, where around 7,500 transplantations have taken place. Thus, there is a dire need for transplants in the country. The growing need for transplantations thereby increases the demand for immunosuppressant drugs. And this is fuelling the growth of the studied market in India.
India-based Cipla Limited manufactures prescription drugs, active pharmaceutical ingredients (APIs) and veterinary products. Its API business unit manufactures over 200 types of generic and complex APIs. The Imusporin 100 Capsule, developed by the company, is used to prevent the body from rejecting a new organ after a heart, liver, or kidney transplant. Cipla has strong R&D capabilities. With its headquarters in Mumbai, the company primarily operates in India.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1.  ORGAN TRANSPLANTATION LEADS THE MARKET BY END-USER
2.2.2.  PHARMACEUTICAL INDUSTRY SHOWING GROWTH TRENDS
2.2.3.  IMPACT OF COVID-19 ON TRANSPLANT RECIPIENTS
2.3. EVOLUTION & TRANSITION OF IMMUNOSUPPRESSANT DRUGS
2.4. PORTER’S FIVE FORCE ANALYSIS
2.4.1.  THREAT OF NEW ENTRANTS
2.4.2.  THREAT OF SUBSTITUTE
2.4.3.  BARGAINING POWER OF SUPPLIERS
2.4.4.  BARGAINING POWER OF BUYERS
2.4.5.  THREAT OF COMPETITIVE RIVALRY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. MARKET DRIVERS
2.7.1.  DEMAND FROM ORGAN TRANSPLANTATION
2.7.2.  RISE IN THE NUMBER OF AUTOIMMUNE DISORDERS
2.8. MARKET RESTRAINTS
2.8.1.  SIDE-EFFECTS OF IMMUNOSUPPRESSANT DRUGS
2.9. MARKET OPPORTUNITIES
2.9.1.  DEMAND FROM EMERGING ECONOMIES
2.9.2.  EXPORTS OF DRUGS AND MEDICINE WORLDWIDE ON RISE
2.10. MARKET CHALLENGES
2.10.1. LACK OF AWARENESS ABOUT ORGAN DONATION
3. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK – BY DRUG CLASS
3.1. CORTICOSTEROIDS
3.2. MONOCLONAL ANTIBODIES
3.3. CALCINEURIN INHIBITORS
3.4. MTOR INHIBITORS
3.5. OTHERS
4. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK - BY DISTRIBUTION CHANNEL
4.1. HOSPITAL PHARMACIES
4.2. RETAIL PHARMACIES
4.3. ONLINE PHARMACIES
5. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET OUTLOOK - BY END-USER
5.1. ORGAN TRANSPLANTATION
5.2. AUTOIMMUNE DISORDERS
5.3. OTHERS
6. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET – REGIONAL OUTLOOK
6.1. CHINA
6.2. JAPAN
6.3. INDIA
6.4. SOUTH KOREA
6.5. ASEAN COUNTRIES
6.6. AUSTRALIA & NEW ZEALAND
6.7. REST OF ASIA-PACIFIC
7. COMPETITIVE LANDSCAPE
7.1. ABBVIE INC
7.2. ALLERGAN (ACQUIRED BY ABBVIE INC)
7.3. ASTELLAS PHARMA INC
7.4. BRISTOL-MYERS SQUIBB COMPANY
7.5. CIPLA LTD
7.6. DR REDDYS LABORATORIES LTD
7.7. F HOFFMANN-LA ROCHE LTD
7.8. GLAXOSMITHKLINE PLC
7.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE)
7.10. JANSSEN PHARMACEUTICALS INC (JOHNSON & JOHNSON SERVICES INC)Â Â Â Â Â Â Â
7.11. MYLAN NV
7.12. NOVARTIS AG
7.13. PFIZER INC
7.14. SANOFI
7.15. VELOXIS PHARMACEUTICALS INC
8. METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY
TABLE 1: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS INDEX
TABLE 3: VENDOR SCORECARD
TABLE 4: SIDE-EFFECTS OF IMMUNOSUPPRESSANT DRUGS
TABLE 5: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
TABLE 6: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY DRUG CLASS, 2019-2028 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, 2019-2028 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
FIGURE 1: EVOLUTION & TRANSITION OF IMMUNOSUPPRESSANT DRUGS
FIGURE 2: PORTER’S FIVE FORCE ANALYSIS
FIGURE 3: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)
FIGURE 4: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
FIGURE 5: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 6: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
FIGURE 7: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 8: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 15: CHINA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 16: JAPAN IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 17: INDIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 18: SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 19: ASEAN COUNTRIES IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 20: AUSTRALIA & NEW ZEALAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
FIGURE 21: REST OF ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)